Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Deloitte
Farmers Insurance
UBS
Cantor Fitzgerald
Argus Health
Mallinckrodt
Johnson and Johnson
Covington
Fish and Richardson
Boehringer Ingelheim

Generated: February 21, 2018

DrugPatentWatch Database Preview

VIRACEPT Drug Profile

« Back to Dashboard

When do Viracept patents expire, and when can generic versions of Viracept launch?

Viracept is a drug marketed by Agouron Pharms and is included in three NDAs.

The generic ingredient in VIRACEPT is nelfinavir mesylate. There are three drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the nelfinavir mesylate profile page.
Drug patent expirations by year for VIRACEPT
Pharmacology for VIRACEPT
Medical Subject Heading (MeSH) Categories for VIRACEPT

US Patents and Regulatory Information for VIRACEPT

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Agouron Pharms VIRACEPT nelfinavir mesylate POWDER;ORAL 020778-001 Mar 14, 1997 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Agouron Pharms VIRACEPT nelfinavir mesylate TABLET;ORAL 020779-001 Mar 14, 1997 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Agouron Pharms VIRACEPT nelfinavir mesylate TABLET;ORAL 021503-001 Apr 30, 2003 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for VIRACEPT

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Agouron Pharms VIRACEPT nelfinavir mesylate POWDER;ORAL 020778-001 Mar 14, 1997 ➤ Sign Up ➤ Sign Up
Agouron Pharms VIRACEPT nelfinavir mesylate TABLET;ORAL 020779-001 Mar 14, 1997 ➤ Sign Up ➤ Sign Up
Agouron Pharms VIRACEPT nelfinavir mesylate TABLET;ORAL 021503-001 Apr 30, 2003 ➤ Sign Up ➤ Sign Up
Agouron Pharms VIRACEPT nelfinavir mesylate TABLET;ORAL 020779-001 Mar 14, 1997 ➤ Sign Up ➤ Sign Up
Agouron Pharms VIRACEPT nelfinavir mesylate TABLET;ORAL 021503-001 Apr 30, 2003 ➤ Sign Up ➤ Sign Up
Agouron Pharms VIRACEPT nelfinavir mesylate TABLET;ORAL 021503-001 Apr 30, 2003 ➤ Sign Up ➤ Sign Up
Agouron Pharms VIRACEPT nelfinavir mesylate TABLET;ORAL 020779-001 Mar 14, 1997 ➤ Sign Up ➤ Sign Up
Agouron Pharms VIRACEPT nelfinavir mesylate POWDER;ORAL 020778-001 Mar 14, 1997 ➤ Sign Up ➤ Sign Up
Agouron Pharms VIRACEPT nelfinavir mesylate POWDER;ORAL 020778-001 Mar 14, 1997 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
Cerilliant
Johnson and Johnson
Federal Trade Commission
US Army
McKesson
UBS
Mallinckrodt
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot